Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved for use in treating thalassaemia major in 1994 and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States. On October 14, 2011, it was approved for use in the US under the FDA's accelerated approval program.
|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||2 to 3 hours|
|Excretion||Renal (75 to 90% in 24 hours)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||139.152 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America. Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.
- Savulescu, J (2004). "Thalassaemia major: The murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
- Staff, Cipla. Cipla's History
- FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
- Viens, A M; Savulescu, J (2004). "Introduction to the Olivieri symposium". Journal of Medical Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
- Brittenham, G. M; Nathan, D. G; Olivieri, N. F; Porter, J. B; Pippard, M; Vichinsky, E. P; Weatherall, D. J (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90, author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.
- Wanless, I. R; Sweeney, G; Dhillon, A. P; Guido, M; Piga, A; Galanello, R; Gamberini, M. R; Schwartz, E; Cohen, A. R (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.
- Cribb, Robert (2019-02-27). "UHN patients given unlicensed drug that led to diabetes, liver dysfunction and one death, study finds". The Star. Toronto. Retrieved 2019-02-27.